<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907175</url>
  </required_header>
  <id_info>
    <org_study_id>HBSLE01</org_study_id>
    <nct_id>NCT04907175</nct_id>
  </id_info>
  <brief_title>Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <brief_summary>
    <textblock>
      This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be&#xD;
      conducted according to US and International Standards of Good Clinical Practice (FDA Title 21&#xD;
      part 312 and International Conference on Harmonization guidelines), applicable government&#xD;
      regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Individual Patient Expanded Access IND has been created per the request of a 65-year-old&#xD;
      woman diagnosed with Systemic Lupus Erythematosus (SLE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Temporarily not available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>System; Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSCs</intervention_name>
    <description>Subject will receive 9 infusions of 200 millions cells each</description>
    <other_name>MSC's</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult individual 18 years of age or older.&#xD;
&#xD;
          -  Cognitively intact and capable of giving informed consent.&#xD;
&#xD;
          -  Clinical diagnosis of Systemic Lupus Erythematosus.&#xD;
&#xD;
          -  Subject has mesenchymal stem cells banked at Hope Biosciences.&#xD;
&#xD;
          -  The patient accepts to receive treatment and to comply with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or&#xD;
             endocrine diseases that in the opinion of the investigator may increase the risks&#xD;
             associated with study participation.&#xD;
&#xD;
          -  Active Alcohol or Drug addiction.&#xD;
&#xD;
          -  Participation in concurrent interventional research studies during this study.&#xD;
&#xD;
          -  Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical&#xD;
             history.&#xD;
&#xD;
          -  Unwillingness to return for follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thanh Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Biosciences Stem Cell Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

